Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US-2017044265-A1 · Feb 16, 2017 · US
Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US10668149B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10668149-B2 |
| Application number | US-201615189577-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 22, 2016 |
| Priority date | Jun 22, 2015 |
| Publication date | Jun 2, 2020 |
| Grant date | Jun 2, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors.
First claim
Opening claim text (preview).
We claim: 1. A method of treating a subject having multiple myeloma (MM), comprising administering to the subject in need thereof an anti-CD38 antibody and a survivin inhibitor for a time sufficient to treat the MM, wherein the anti-CD38 antibody comprises a heavy chain complementarity determining region (HCDR) 1, HCDR2 and a HCDR3 of SEQ ID NOs: 6, 7 and 8, respectively, and a light chain complementarity determining region (LCDR) 1, a LCDR2 and a LCDR3 of SEQ ID NOs: 9, 10 and 11, respectively, and is an IgG1 isotype, and wherein the survivin inhibitor is YM155. 2. The method of claim 1 , wherein the anti-CD38 comprises a heavy chain variable region (VH) of SEQ ID NO: 4 and a light chain variable region (VL) of SEQ ID NO:5. 3. The method of claim 1 , wherein the anti-CD38 antibody induces CD38-positive cell killing by antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement- dependent cytotoxicity (CDC) or apoptosis. 4. The method of claim 1 , wherein the anti-CD38 antibody and the survivin inhibitor are administered simultaneously, sequentially or separately. 5. The method of claim 4 , wherein the anti-CD38 antibody is administered intravenously. 6. The method of claim 1 , wherein the anti-CD38 antibody comprises a heavy chain of SEQ ID NO: 12 and a light chain of SEQ ID NO: 13.
Assignees
Inventors
Classifications
comprising antibodies · CPC title
containing further heterocyclic rings · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
against molecules with a "CD"-designation, not provided for elsewhere · CPC title
Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10668149B2 cover?
- The present invention relates to combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors.
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K39/3955. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).